Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › bortezomib

bortezomib

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of bortezomib

184 trials tracked of bortezomib: 21 in phase 3 or 4 and 12 with published results. The most-cited published study has 647 citations.

184Trials tracked
21Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 3 Phase 3 18 Phase 2 152 Phase 1 8 Other / NA 3
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Completed · 647 cited
  2. Phase 3 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Completed · 400 cited
  3. Phase 3 Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 381 cited
  4. Phase 3 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) Completed · 227 cited
  5. Phase 3 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Completed · 140 cited
  6. Phase 3 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma Completed · 129 cited
Show 44 more trials
  1. Phase 3 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Completed · 120 cited
  2. Phase 3 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Completed · 103 cited
  3. Phase 3 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed · 101 cited
  4. Phase 3 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma Completed · 31 cited
  5. Phase 3 Velcade (Bortezomib) Consolidation After Transplant Completed · 17 cited
  6. Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed · 2 cited
  7. Phase 4 Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients Completed
  8. Phase 4 Desensitization in Kidney Transplantation Completed
  9. Phase 3 Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Completed
  10. Phase 3 Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone Completed
  11. Phase 3 A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma Completed
  12. Phase 3 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Completed
  13. Phase 3 Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Completed
  14. Phase 3 Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma Completed
  15. Phase 3 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed
  16. Phase 2 Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
  17. Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide Completed
  18. Phase 2 Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Completed
  19. Phase 2 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Completed
  20. Phase 2 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD Completed
  21. Phase 2 Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  22. Phase 2 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed
  23. Phase 2 Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed
  24. Phase 2 Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma Completed
  25. Phase 2 Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant Completed
  26. Phase 2 Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Completed
  27. Phase 2 Randomized Trial for Mixed Acute Rejection Completed
  28. Phase 2 Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  29. Phase 2 Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma Completed
  30. Phase 2 Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma Completed
  31. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  32. Phase 2 VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma Completed
  33. Phase 2 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Completed
  34. Phase 2 Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  35. Phase 2 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma Completed
  36. Phase 2 Optimising Renal Outcome in Myeloma Renal Failure Completed
  37. Phase 2 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Completed
  38. Phase 2 Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed
  39. Phase 2 IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients Completed
  40. Phase 2 Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Completed
  41. Phase 2 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach Completed
  42. Phase 2 A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) Completed
  43. Phase 2 Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL Completed
  44. Phase 2 Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Completed

Showing the 50 most-cited and recently-updated of 184 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
Oncology FDA Approval
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
FDA May 5, 2026
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Oncology Cohort
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
medRxiv Apr 16, 2026
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis
Hematology Cohort
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis Small study links daratumumab resistance to immune changes in light-chain amyloidosis
An observational cohort study of 30 patients with primary light-chain amyloidosis treated with daratumumab-bortezomib-dexamethasone found th…
Patients with weaker responses to amyloidosis treatment showed lower gene activity before therapy and increased immune stress during treatme…
medRxiv Apr 6, 2026
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Oncology Phase II
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial Can a new drug combination help people with aggressive multiple myeloma? Early results show promise
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Mar 30, 2026